What’s Next for Bio-techne Corp (NASDAQ:TECH) After Having Less Shares Shorted?

July 14, 2018 - By Elena Maslow

Bio-Techne Corporation (NASDAQ:TECH) Logo

Investors sentiment increased to 1.32 in 2018 Q1. Its up 0.34, from 0.98 in 2017Q4. It improved, as 14 investors sold Bio-Techne Corporation shares while 89 reduced holdings. 53 funds opened positions while 83 raised stakes. 35.01 million shares or 1.47% less from 35.53 million shares in 2017Q4 were reported.
Bnp Paribas Arbitrage Sa holds 0% or 9,743 shares. Foundry Prns Limited Liability accumulated 17,564 shares. Amalgamated Bancorp holds 0.03% in Bio-Techne Corporation (NASDAQ:TECH) or 8,280 shares. Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% in Bio-Techne Corporation (NASDAQ:TECH). Liberty Mutual Gru Asset Management accumulated 7,378 shares. Oakbrook Invs Lc holds 0.03% of its portfolio in Bio-Techne Corporation (NASDAQ:TECH) for 3,270 shares. Aqr Mngmt Limited Company holds 0.01% of its portfolio in Bio-Techne Corporation (NASDAQ:TECH) for 54,615 shares. Stephens Investment Mngmt Group Limited Liability Com, a Texas-based fund reported 114,740 shares. Segall Bryant Hamill Ltd has invested 1.09% in Bio-Techne Corporation (NASDAQ:TECH). Mason Street Advsr Limited Liability Company owns 18,822 shares for 0.07% of their portfolio. Btim accumulated 137,529 shares. Paloma Prtn Mngmt accumulated 2,820 shares or 0.01% of the stock. Pub Employees Retirement Association Of Colorado accumulated 128,153 shares. 50,698 were reported by Bogle Invest Mgmt Lp De. Veritable Lp owns 2,814 shares.

Since February 13, 2018, it had 0 insider buys, and 3 insider sales for $2.13 million activity. Dinarello Charles A sold $680,303 worth of stock. Eansor Norman David sold 1,136 shares worth $164,932.

The stock of Bio-techne Corp (NASDAQ:TECH) registered a decrease of 6.01% in short interest. TECH’s total short interest was 916,100 shares in July as published by FINRA. Its down 6.01% from 974,700 shares, reported previously. With 152,400 shares average volume, it will take short sellers 6 days to cover their TECH’s short positions. The short interest to Bio-techne Corp’s float is 2.45%.

The stock decreased 0.14% or $0.21 during the last trading session, reaching $153.11. About 108,484 shares traded. Bio-Techne Corporation (NASDAQ:TECH) has risen 33.83% since July 14, 2017 and is uptrending. It has outperformed by 21.26% the S&P500.

Bio-Techne Corporation, together with its subsidiaries, develops, makes, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. The company has market cap of $5.75 billion. It operates through three divisions: Biotechnology, Protein Platforms, and Diagnostics. It has a 51.73 P/E ratio. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets.

Bio-Techne Corporation (NASDAQ:TECH) Ratings Coverage

Among 6 analysts covering Bio-Techne Corporation (NASDAQ:TECH), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Bio-Techne Corporation has $185 highest and $142.0 lowest target. $161.50’s average target is 5.48% above currents $153.11 stock price. Bio-Techne Corporation had 9 analyst reports since January 18, 2018 according to SRatingsIntel. Leerink Swann maintained the stock with “Buy” rating in Thursday, May 3 report. Robert W. Baird maintained the shares of TECH in report on Tuesday, February 6 with “Buy” rating. The stock has “Hold” rating by Deutsche Bank on Wednesday, June 27. The stock has “Hold” rating by Stephens on Wednesday, February 7. Deutsche Bank maintained it with “Buy” rating and $165 target in Thursday, May 3 report. The stock of Bio-Techne Corporation (NASDAQ:TECH) earned “Buy” rating by Robert W. Baird on Thursday, January 18. Craig Hallum maintained Bio-Techne Corporation (NASDAQ:TECH) on Wednesday, February 7 with “Buy” rating. The firm has “Buy” rating given on Thursday, March 1 by Deutsche Bank.

More recent Bio-Techne Corporation (NASDAQ:TECH) news were published by: Streetinsider.com which released: “Bio-Techne (TECH) Announces Antibody Validation Initiative Using CRISPR Gene Editing Technology Across Broad …” on July 10, 2018. Also Money.Cnn.com published the news titled: “Sell tech! Morgan Stanley’s warning to investors” on July 09, 2018. Seekingalpha.com‘s news article titled: “BioTechne to buy Exosome Diagnostics” with publication date: June 25, 2018 was also an interesting one.

Bio-Techne Corporation (NASDAQ:TECH) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.